Agilent Technologies (A) has completed the acquisition of Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners, the company said Thursday.
The company said Biocare Medical will be integrated into its Life Sciences and Diagnostics Markets Group, strengthening its pathology portfolio across clinical and research settings.
Agilent said the deal is expected to be accretive to its top-line growth rate, margin profile and non-instrument revenue mix in the first year, with earnings per share accretion anticipated approximately 12 months after closing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments